Лечение детей с остеосаркомой
https://doi.org/10.25789/YMJ.2019.65.29
Аннотация
В статье приведены статистические данные, описывающие заболеваемость остеосаркомой у детей, классификация остеосаркомы, описание основных локализаций, а также подробное описание существующих протоколов лечения, включая персонализированную терапию. Подробно описаны литературные данные – результаты лечения детей с остеосаркомой с применением различных курсов химиотерапии, а также новые подходы к лечению, включая персонализированную терапию. Отмечено, что результаты лечения детей с первичной метастатической остеосаркомой, рецидивом и рефрактерным течением заболевания остаются неудовлетворительными.
Ключевые слова
Об авторах
Э. Р. Сенжапова
ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет)
Россия
Россия
Сенжапова Эльмира Рифатовна – к.м.н., н.с.
М. Ю. Рыков
НИИ ДОГ ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России;
ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет)
Россия
Россия
Рыков Максим Юрьевич – к.м.н., зам. Директора;
Доцент
гл. внештат. детский специалист онколог Минздрава России по центральному федеральному округу
Список литературы
1. Пунанов Ю.А. Результаты комбинированного лечения детей и подростков с остеосаркомой / Ю.А. Пунанов, Т.В. Андреева, Г.И. Гафтон, Ю.В Гудзь, С.А. Сафонова, В.В. Набоков, В.И. Новик // Онкопедиатрия. – 2014. – № 1(2). – C. 49-53.
2. Avella M. Adjuvant chemotherapy with six drugs (Adriamycin, methotrexate, cisplatinum, bleomycin, cyclophosphamide and dactinomycin) for non-metastatic high grade osteosarcoma of the extremities. Results of 32 patients and comparison to 127 patients concomitantly treated with the same drugs in a neoadjuvant form / M. Avella, G. Bacci, D.J. McDonald // Chemioterapia. – 1988. – №7(2). – P. – 133-137.
3. Bacci G. Long-Term Outcome for Patients With Nonmetastatic Osteosarcoma of the Extremity Treated at the Istituto Ortopedico Rizzoli According to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: An Updated Report / G. Bacci, S. Ferrari, F. Bertoni // Journal of clinical oncology. – 2000. – №18(24). – P.4016-4027. doi: 10.1200/JCO.2000.18.24.4016.
4. Boye K. High-Dose Chemotherapy with Stem Cell Rescue in the Primary Treatment of Metastatic and Pelvic Osteosarcoma: Final Results of the ISG/SSG II Study / K. Boye, A.B. Del Prever, E. Eiksson // Pediatric blood cancer. – 2014. – №61(5). – P. 840-845. doi: 10.1002/pbc.24868.
5. Cui Q. Relationship between hypermetylated MGMT gene and osteosarcoma necrosis rate after chemotherapy / Q. Cui, W. Jiang, J. Guo // Pathology oncology research. – 2011. – №17. – P. 587-591. doi: 10.1007/s12253-010-9354-7.
6. Daw N.C. Metastatic Osteosarcoma. Results of Two Consecutive Therapeutic Trials at St. Jude Children’s Research Hospital / N.C. Daw, C.A. Billups, C. Rodriques-Galindo // Cancer. – 2006. – №106. – P. 403–412. doi: 10.1002/cncr.21626.
7. Daw N.C. Frontline Treatment of Localized Osteosarcoma Without Methotrexate: results of the St. Jude Children’s research hospital OS99 trial / N.C. Daw, M.D. Neel, B.N. Rao // Cancer. – 2011. – №117(12). – P. 2770–2778. doi: 10.1002/cncr.25715.
8. Ebb D. Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children’s Oncology Group / D. Ebb, G. Holcombe, M. Karen // Journal of clinical oncology. – 2012. – №30(20). – P. 2245-2551. doi: 10.1200/JCO.2011.37.4546.
9. Ferrari S. Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin With or Without Ifosfamide in Nonmetastatic Osteosarcoma of the Extremity: An Italian Sarcoma Group Trial ISG/OS-1 / S. Ferrari, P. Ruqqieri, G. Cefalo // Journal of clinical oncology. – 2012. – №30(17). – P. 2112-2118. doi: 10.1200/JCO.2011.38.4420.
10. Ferrari S. Neoadjuvant Chemotherapy With High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, and Doxorubicin for Patients With Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma Groups / S. Ferrari, S. Smeland, M. Mercuri // Journal of clinical oncology. – 2005. – №23(34). – P. 8845-8852. doi: 10.1200/JCO.2004.00.5785.
11. Fletcher, C.D.M. Pathology and Genetics of Tumours of Soft Tissue and Bone / C.D.M. Fletcher, J.A. Bridge, J.A. Hogendoorn // WHO classification 2013. – http://sarcomahelp.org/reviews/who-classification-sarcomas.html
12. Goorin A.M. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial / A.M. Goorin, M.B. Harris, M. Bernstein // Journal of clinical oncology. – 2002. – №2. – P. 426-433. doi: 10.1200/JCO.2002.20.2.426.
13. Goorin A.M. Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651 / A.M. Goorin, D.J. Shwartzentruber, M. Devidas // Journal of clinical oncology. – 2003. – №21. – P. 1574-1580. doi: 10.1200/JCO.2003.08.165.
14. Gorlick R. Expression of HER2/erbB-2 Correlates With Survival in Osteosarcoma / R. Gorlick, A.G. Huvos, G. Heller // Journal of clinical oncology. – 1999. – №17. – P. 2781-2788. doi: 10.1200/JCO.1999.17.9.2781.
15. Gorlick S. HER-2 Expression is Not Prognostic in Osteosarcoma; A Children’s Oncology Group Prospective Biology Study / S. Gorlick, D.A. Barkauskas, M. Krailo // Pediatric blood cancer. – 2014. – №61. – P. 1558-1564. doi: 10.1002/pbc.25074.
16. Han G. C-MYC overexpression promotes osteosarcoma cell invasion via activation of MEK-ERK pathway / G. Han, Y. Wang, W. Bi // Oncology research. – 2012. – №20. – P. 149-156. doi: 10.3727/096504012X13522227232237.
17. Hattinger C.M. ERCC1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy / C.M. Hattinger, F. Michelacci, F. Sella // Histopathology. – 2015. – №67(3). – P. 338-347. doi: 10.1111/his.12653.
18. Hegyi M. Good Prognosis of Localized Osteosarcoma in Young Patients Treated With Limb-Salvage Surgery and Chemotherapy / M. Hegyi, A.F. Semsei, Z. Jakab // Pediatric Blood Cancer. – 2011. – №57. – P. 415–422. doi: 10.1002/pbc.23172.
19. Hinds P.S. Aggressive treatment of nonmetastatic osteosarcoma improves health-related quality of life in children and adolescents / P.S. Hinds, J.S. Gattuso, C.A. Billups // European journal of cancer. – 2009. – №45. – P. 2007-2014. doi: 10.1016/j.ejca.2009.04.020.
20. Isakoff M.S. Poor Survival for Osteosarcoma of the Pelvis: A Report from the Children’s Oncology Group / M.S. Isakoff, D.A. Barkauskas, D. Ebb // Clinical Orthopedics Related Research. – 2012. – №470. – P. 2007–2013. doi: 10.1007/s11999-012-2284-9.
21. Isakoff M.S. Osteosarcoma: current treatment and a collaborative pathway to success / M.S. Isakoff, S.S. Bielack, P. Meltzer // Journal of clinical oncology. – 2015. – №33(27) – P. 3029-3035. doi: 10.1200/JCO.2014.59.4895.
22. Iwamoto Y. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO95J / Y. Iwamoto, K. Tanaka, K. Isu // Journal of orthopedic science. – 2009. – №14. – P. 397–404. doi: 10.1007/s00776-009-1347-6.
23. Le Deley M.C. SFOP OS94: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients / M.C. Le Deley, J.M. Guinebretiere, V.C. Gentet // European journal of cancer. – 2007. – №43. – P.752-761. doi: 10.1016/j.ejca.2006.10.023.
24. Li J.I. CD133 expression in osteosarcoma and derivation of CD133 cells / J.I. Li, X.Y. Zhong, Z.Y. Li // Molecular medicine reports. – 2013. – №7. – P. 577-584. doi: 10.3892/mmr.2012.1231.
25. Marina N.M. Comparison of MAPIE versus MAP in patients with poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS1): an open-label, international, randomized controlled trial / N.M. Marina, S. Smeland, S.S. Bielack // Lancet oncology. – 2016. – №17(10). – P. 1396-1408. doi: 10.1016/S1470-2045(16)30214-5.
26. Meyers P.A. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma / P.A. Meyers, J.H. Healeya, A.J. Choua // Cancer. – 2011. – №117(8). – P. 1736–1744. doi: 10.1002/cncr.25744.
27. Meyers P.A. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival – a report from the Children’s Oncology Group / P.A. Meyers, C.L. Schwartz, M.D. Krailo // Journal of clinical oncology. – 2008. – №28(9). – P. 633-638. doi: 10.1200/JCO.2008.14.0095.
28. Nguyen A. Role of topoisomerases in pediatric high grade osteosarcomas: TOP2A gene is one of the unique molecular biomarkers of chemoresponse / A. Nguyen, C. Lasthaus, E. Guerin // Cancer. – 2013. – №5. – P. 662-675. doi: 10.3390/cancers5020662.
29. Petrilli S. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: Prognostic Factors and Impact on Survival / S. Petrilli, B. de Camargo, V.O. Filho // Journal of clinical oncology. – 2006. – №24(7). – P. 1161-1168. doi: 10.1200/JCO.2005.03.5352.
30. Pitano-Garcia A. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression / A. Pitano-Garcia, M. Zalacain, L. Marrodan // Journal of pediatrics. – 2009. – №154(5). – P. 688-693. doi: 10.1016/j.jpeds.2008.
31. Smeland S. Event-free survival and overall survival in 2,253 patients with osteosarcoma registered to EURAMOS-1 / S. Smeland, J.S. Whelan, S.S. Bielack // Journal of clinical oncology. – 2015. – №33. – P. 1051.
32. Smeland S. Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma / S. Smeland, O.S. Bruland, L. Hjorth // Acta Orthopaedica. – 2011. – №82(2). – P.211–216. doi: 10.3109/17453674.2011.566141.
33. Souhami R.L. Randomised trial of two regimens of chemotherapy inoperable osteosarcoma: a study of the European Osteosarcoma Intergroup / R.L. Souhami, A.W. Craft, J.W.V. der Eijken // The Lancet. – 1997. – №350. – P. 911-917. doi: 10.1016/S0140-6736(97)02307-6.
34. Tu B. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3 / B. Tu, J. Zhu, S. Liu // Oncotarget. – 2016. – №7(30). – P. 48296-48308. doi: 10.18632/oncotarget.10219.
35. Xiao X. Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma / X. Xiao, W. Wang, H. Zhang // Tumour biology. – 2015. – №36(4). – P. 2437-35. doi: 10.1007/s13277-014-2853-5.
Рецензия
Для цитирования:
Сенжапова Э.Р., Рыков М.Ю. Лечение детей с остеосаркомой. Якутский медицинский журнал. 2019;(1):94-102. https://doi.org/10.25789/YMJ.2019.65.29
For citation:
Senzhapova E.R., Rykov M.Yu. Treatment of children with osteosarcoma. Yakut Medical Journal. 2019;(1):94-102. https://doi.org/10.25789/YMJ.2019.65.29
Просмотров:
0
Послать статью по эл. почте 